NSIM
MYGN icon

North Star Investment Management’s Myriad Genetics MYGN Stock Holding History

North Star Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$3K – 1076
2018
Q4 		$3K Hold
100
– – ﹤0.01% 965
2018
Q3 		$5K Buy
+100
New +$4.45K ﹤0.01% 938

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

North Star Investment Management's MYGN Position: Q1 2019 in Review

North Star Investment Management sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 100 shares — an estimated $3K sold.

North Star Investment Management first reported a position in MYGN in Q3 2018 and held it in 2 quarters. The position peaked at $5K in Q3 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

  • North Star Investment Management reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
  • North Star Investment Management sold 100 Myriad Genetics shares in Q1 2019, an estimated $3K.
  • North Star Investment Management first reported a position in Myriad Genetics in Q3 2018 and held it in 2 quarters.
  • North Star Investment Management's Myriad Genetics position peaked at $5K in Q3 2018.
  • 262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on North Star Investment Management's 13F filing for Q1 2019, filed 10 Apr 2019.